IP Library Granted Patent US 8,916,568
Granted Patent B2
US 8,916,568 · App. 14/012,330 · Granted Dec 23, 2014

Method of using diketopiperazines and composition containing them

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,916,568
App. No.
14/012,330
Granted
Dec 23, 2014
Kind
B2
Abstract

The invention provides a method of inhibiting the effects of platelet activating factor (PAF). For instance, a disease or condition mediated by PAF (particularly inflammation) can be treated or platelet aggregation can be inhibited. The invention also provides a method of inhibiting the production and/or release of interleukin 8 (IL-8) by cells. The effects of PAF and the production and/or release of IL-8 are inhibited according to the invention by a compound of the formula: wherein R 1 and R 2 are defined in the application, or a physiologically-acceptable salt thereof. The invention also provides pharmaceutical compositions comprising these compounds.

Claims (5)

1. A pharmaceutical composition for inhibiting inflammation comprising a pharmaceutically-acceptable carrier and an amount of active ingredient effective to inhibit inflammation, wherein the active ingredient is 3-methyl-2,5-diketopiperazine-6-acetic acid or a physiologically-acceptable salt thereof, and wherein the composition is an isotonic formulation.

2. The pharmaceutical composition of claim 1 , wherein the composition is formulated for parenteral administration.

3. The pharmaceutical composition of claim 1 , wherein the composition is formulated for injection.

4. The pharmaceutical composition of claim 1 , wherein the active ingredient is present in the composition at a concentration of at least about 20 μM.

5. The pharmaceutical composition of claim 1 , wherein the active ingredient is present in the composition at a concentration of about 20 μM.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2014
From: BAR-OR, DAVID; THOMAS, GREG; CURTIS, C. GERALD; RAO, NAGARAJA K.R.
To: DMI BIOSCIENCES, INC.
Reel/Frame 032028/0375 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2014
From: DMI BIOSCIENCES, INC.
To: DMI ACQUISITION CORP.
Reel/Frame 032028/0464 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2014
From: DMI ACQUISITION CORP.
To: AMPIO PHARMACEUTICALS, INC.
Reel/Frame 032028/0578 →